[
  {
    "sentence": "The heatmap demonstrates the ratio between mean fragments per kilobase of transcript per million mapped reads (FPKM) value of each group and the average of mean FPKM values of the two groups. (J) Measurements of signal intensity of the cytokines, chemokines, and growth factors represented on the protein arrays performed on test (Tslp-PyMttg) and control (PyMttg TslprKO) CD4+ T cells supernatants related to arrays shown in Fig. 3 E.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Note that Il4KO, TnfKO, and IfngKO tumor growth data are also shown in Fig. 6, A–C (two-way ANOVA). (J) Representative images of H&E-stained PyMtOvatg TslprKO breast tumors in Tslptg TslprKO mice injected with IfngKO versus TslprKO CD4+ T cells (scale bar: 100 μm). (K and L) Spider plots of primary PyMtOvatg TslprKO tumor growth in Tslptg TslprKO mice injected with Il3KO (n = 6, 4/6 tumors were <0.5 cm3 at the endpoint) versus WT (n = 6, 5/6 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA; K) and WT CD4+ T cells in combination with anti–IL-5 plus anti–GM-CSF blocking antibodies (ab, n = 9, 6/9 tumors were <0.5 cm3 at the endpoint) versus WT CD4+ T cells and Rat IgG isotype control antibody (n = 10, 8/10 tumors were <0.5 cm3 at the endpoint; L; two-way ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Note that Il3KO and WT CD4+ T cells plus anti–IL-5 plus anti–GM-CSF blocking antibodies tumor growth data are also shown in Fig. 6, D and E. (M) Representative images of HC11 mammosphere immunofluorescence staining after exposure to supernatants (sup.) derived from splenic Il3KO versus WT CD4+ T cells stimulated once with anti-CD3, anti-CD28, and TSLP for 3 d ex vivo.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "1 d after adoptive T cell transfer, primary breast tumors from PyMttg TslprKO or MMTV-PyMT-mCherry-Ovatg, Tslpr−/− mice (PyMtOvatg TslprKO, expressing OVA in tumor cells; Engelhardt et al., 2012) on the C57BL/6 background were implanted into the abdominal mammary fat pad of recipient Tslptg TslprKO mice, which were then monitored for breast tumor growth over time (Fig. 5 A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PyMttg TslprKO primary breast tumor cells generated significantly smaller tumors in Tslptg TslprKO mice that received WT CD4+ T cells compared with TslprKO CD4+ T cells (P = 0.0087; Fig. 5 B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The breast cancer suppression in the Tslptg TslprKO + WT CD4+ T cell group was more pronounced when the tumor cells expressed OVA antigen (PyMtOvatg TslprKO, P < 0.0001; Fig. 5 C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Enhanced protection against PyMtOvatg TslprKO tumors in mice that received WT CD4+ T cells resulted in long-term survival of 67% of these animals (P = 0.0002, Fig. 5 D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Although the implanted PyMtOvatg TslprKO tumor (donor tumor) had a high histological grade, recipient mice in the Tslptg TslprKO + WT CD4+ T cell (test) group developed low-grade tumors (P = 0.0005, Fig. 5, E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The majority of Tslptg TslprKO mice with WT CD4+ T cells either did not have a detectable tumor focus on the histology or developed cystic structures surrounded by fibrotic tissue at the site of implanted tumor at the completion of the study, which corresponded to the lack of tumor growth and long-term survival of these animals (Fig. 5 F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Breast cancer suppression in the test group was associated with large CD4+ T and few CD103+ CD4+ TRM cell infiltrates surrounding the low-grade tumors (Fig. 5 G).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Transferring congenically marked (CD45.1+) WT CD4+ T cells into Tslptg TslprKO mice revealed that the majority of these cells became GATA3+ Th2 cells, which actively proliferated in PyMtOvatg TslprKO tumors (Fig. 5, H–K).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "CD4+ T cell immunity against OVA-positive tumor cells did not affect the nearby normal mammary glands (Fig. 5, L and M).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Likewise, TSLP-stimulated WT CD4+ T cells in Tslptg TslprKO mice did not cause inflammation in skin, lung, or normal mammary glands (Fig. 5 N).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As expected, OTII T cells protected Tslptg TslprKO mice from PyMtOvatg TslprKO tumor development (P = 0.0107; Fig. 5 O).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "OTII T cells reverted high-grade PyMtOvatg TslprKO donor tumor into low-grade fibrocystic structures in the recipient Tslptg TslprKO animals (Fig. 5 P).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, OTII T cells were not able to protect Tslptg TslprKO mice from PyMttg TslprKO tumors, which lacked OVA expression and grew larger in the presence of OTII compared with TslprKO T cells (P = 0.0216; Fig. 5, Q and R).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "1 d after adoptive T cell transfer, primary breast tumors from PyMttg TslprKO or MMTV-PyMT-mCherry-Ovatg, Tslpr−/− mice (PyMtOvatg TslprKO, expressing OVA in tumor cells; Engelhardt et al., 2012) on the C57BL/6 background were implanted into the abdominal mammary fat pad of recipient Tslptg TslprKO mice, which were then monitored for breast tumor growth over time (Fig. 5 A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PyMttg TslprKO primary breast tumor cells generated significantly smaller tumors in Tslptg TslprKO mice that received WT CD4+ T cells compared with TslprKO CD4+ T cells (P = 0.0087; Fig. 5 B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The breast cancer suppression in the Tslptg TslprKO + WT CD4+ T cell group was more pronounced when the tumor cells expressed OVA antigen (PyMtOvatg TslprKO, P < 0.0001; Fig. 5 C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Enhanced protection against PyMtOvatg TslprKO tumors in mice that received WT CD4+ T cells resulted in long-term survival of 67% of these animals (P = 0.0002, Fig. 5 D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Although the implanted PyMtOvatg TslprKO tumor (donor tumor) had a high histological grade, recipient mice in the Tslptg TslprKO + WT CD4+ T cell (test) group developed low-grade tumors (P = 0.0005, Fig. 5, E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The majority of Tslptg TslprKO mice with WT CD4+ T cells either did not have a detectable tumor focus on the histology or developed cystic structures surrounded by fibrotic tissue at the site of implanted tumor at the completion of the study, which corresponded to the lack of tumor growth and long-term survival of these animals (Fig. 5 F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Breast cancer suppression in the test group was associated with large CD4+ T and few CD103+ CD4+ TRM cell infiltrates surrounding the low-grade tumors (Fig. 5 G).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Transferring congenically marked (CD45.1+) WT CD4+ T cells into Tslptg TslprKO mice revealed that the majority of these cells became GATA3+ Th2 cells, which actively proliferated in PyMtOvatg TslprKO tumors (Fig. 5, H–K).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "CD4+ T cell immunity against OVA-positive tumor cells did not affect the nearby normal mammary glands (Fig. 5, L and M).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Likewise, TSLP-stimulated WT CD4+ T cells in Tslptg TslprKO mice did not cause inflammation in skin, lung, or normal mammary glands (Fig. 5 N).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As expected, OTII T cells protected Tslptg TslprKO mice from PyMtOvatg TslprKO tumor development (P = 0.0107; Fig. 5 O).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "OTII T cells reverted high-grade PyMtOvatg TslprKO donor tumor into low-grade fibrocystic structures in the recipient Tslptg TslprKO animals (Fig. 5 P).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, OTII T cells were not able to protect Tslptg TslprKO mice from PyMttg TslprKO tumors, which lacked OVA expression and grew larger in the presence of OTII compared with TslprKO T cells (P = 0.0216; Fig. 5, Q and R).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Note that Il3KO CD4+ T cells plus anti–IL-5/GM-CSF antibodies tumor growth data are also shown in Fig. 6 F. (G) Representative H&E and CD4-immunostained images of PyMtOvatg TslprKO primary tumors developed in Tslptg TslprKO mice injected with Il3KO CD4+ T cells plus anti–IL-5 and anti–GM-CSF blocking antibodies (test) versus TslprKO CD4+ T cells plus isotype control antibody (negative control) and WT CD4+ T cells plus isotype control antibody (positive control). (H) Distribution of histological grades of PyMtOvatg TslprKO primary tumors developed in Tslptg TslprKO mice injected with Il3KO CD4+ T cells plus anti–IL-5 and anti–GM-CSF blocking antibodies (test, n = 13) versus TslprKO CD4+ T cells plus isotype control antibodies (negative control, n = 14) and WT CD4+ T cells plus isotype control antibodies (positive control, n = 4, Fisher’s exact test). (I) Quantification of CD4+ T cells in PyMtOvatg TslprKO primary tumors developed in Tslptg TslprKO mice injected with Il3KO CD4+ T cells plus anti–IL-5 and anti–GM-CSF blocking antibodies (test, n = 13) versus TslprKO CD4+ T cells plus isotype control antibody (negative control, n = 12) and WT CD4+ T cells plus isotype control antibody (positive control, n = 4).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Recipient mice were monitored for breast tumor growth over time (Fig. 6 G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Although the transferred CD45.1+ WT CD4+ T cells acquired Th2 phenotype in PyMtOvatg Csf2rbKO Csf2rb2KO tumors, they failed to suppress tumor growth, extend animals’ survival, or promote tumor differentiation compared with TslprKO CD4+ T cells in Tslptg TslprKO mice (Fig. 6, H–N).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  }
]